OpportunityTitle: PDX Data Commons and Coordinating Center (PDCCC) for the PDX Development and Trial Centers Research Network (PDXNet) (U24)
AdditionalInformationOnEligibility: Other Eligible Applicants include the following:  Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Description: The purpose of this funding opportunity announcement (FOA) is to establish a PDXNet Data Commons and Coordinating Center (PDCCC). PDCCC will interact with and coordinate with the PDX (Patient-Derived Xenograft) Development and Trial Centers Research Network (PDXNet) comprised of four PDX Development and Trial Centers (PDTCs, to be supported by companion FOA, RFA-CA-17-003) in a collaborative network. The PDXNet is a National Cancer Institute (NCI) program established to coordinate collaborative, large-scale development and pre-clinical testing of targeted therapeutic agents in patient-derived models to advance the vision of cancer precision medicine. The goals for PDTCs include: development of new PDX models and methods for preclinical testing of single agents and drug combinations; and using the newly established models as well as other existing well-characterized PDX models for studies of drug responses. The PDCCC will serve as the coordinating and data analysis center of the PDXNet. It is expected that the outcomes of PDXNet research will be particularly important for the prioritization of combinations of agents in the portfolio of NCI Investigational New Drugs (NCI-IND agents), which are evaluated clinically in the NCIs Experimental Therapeutic Clinical Trials Network (ETCTN).
GrantorContactEmailDescription: If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
GrantorContactText: NIH OER Webmaster&lt;br/&gt;FBOWebmaster@OD.NIH.GOV&lt;br/&gt;